NLS Pharmaceuticals (NLSP)

MarketBeat, QualityStocks, bullseyeoptiontrading, StockWireNews, Small Cap Firm, MarketClub Analysis, INO Market Report, Fierce Analyst and Early Bird reported earlier on NLS Pharmaceuticals (NLSP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NLS Pharmaceutics Ltd (NASDAQ: NLSP) is a biopharmaceutical firm that is focused on discovering and developing drug therapies for the treatment of neurodevelopmental disorders as well as complex and rare central nervous system disorders.

The firm has its headquarters in Stans, Switzerland and was incorporated in June 2015 by Alexander Zwyer and Ronald Hafner. It operates as part of the scientific research and development services industry, under the health care sector. The firm serves consumers around the globe.

The company’s objective is to develop effective and safe drugs that measurably improve behavioral and mental disorders. Its mission is to safeguard longevity and life by empowering the brain through various stages of life. The company’s tangible assets are held in the United States.

The enterprise develops treatments for central nervous system disorders like idiopathic hyperinsomnia and narcolepsy, among other rare sleep disorders. Its product candidates include a formulation known as Nolazol, which is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). ADHD affects about 11% of children aged between 4-11 in the United States. It also develops a formulation dubbed Quilience, which has been developed to treat excessive daytime sleepiness and cataplexy. Cataplexy refers to a sudden loss of muscle tone when an individual is awake, which causes a loss of voluntary muscle control and muscle weakness.

The company’s Quilience formulation has been granted Orphan Drug Designations in both Europe and the U.S. It believes the formulation has the potential to meet the needs of most patients with narcolepsy, whose clinical needs aren’t being met by current medications. The success and approval of this treatment will not only benefit patients with this indication but also bring in additional revenue and investors into the company.

NLS Pharmaceuticals (NLSP), closed Tuesday's trading session at $0.2701, up 82.1308%, on 305,495,715 volume. The average volume for the last 3 months is 680,787 and the stock's 52-week low/high is $0.1112/$1.53.

GeoVax Labs (GOVX)

Wall Street Resources, QualityStocks, IRGnews Alert, Standout Stocks, MarketClub Analysis, MarketBeat, Penny Performers, BUYINS.NET, InvestorPlace, SmallCapStockPlays, SmallCapVoice, Stock News Now, Stock Stars, Stockpalooza, Premium Stock Alerts, INO Market Report, FeedBlitz, DrStockPick, M2 Communications, Daily Market Beat, CoolPennyStocks, HotOTC, Money Wealth Matters, PennyOmega, PoliticsAndMyPortfolio, Prism MarketView, ProActive Capital, Schaeffer's, The Online Investor, The Street, TradersPro, Wall Street Mover and PennyTrader.com reported earlier on GeoVax Labs (GOVX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GeoVax Labs Inc. (NASDAQ: GOVX) (FRA: E8L) is a clinical stage biotechnology firm which is engaged in the development, manufacture, testing, licensing and commercialization of human vaccines that prevent and fight ailments caused by HIV-1 and other infectious agents.

The firm operates as part of the biotechnology research services industry and has its headquarters in Smyrna, Georgia. The company was founded in 1988 by Donald G. Hildebrand and Harriet Latham Robinson.

This firm is party to partnership and collaboration agreements with Leidos Inc., the University of California, the Geneva Foundation, Viamune Inc., American Gene Technologies International Inc., the Burnet Institute, the Scripps Research Institute, the University of Maryland Institute of Human Virology, University of Texas Medical Branch, Georgia State University Research Foundation, University of Pittsburgh, Emory University, U.S. Naval Research Laboratory, U.S. Army Research Institute of Infectious Disease, U.S. Department of Defense, the CDC, the HIV Vaccines Trial Network and the National Institute of Allergy and Infectious Diseases of the NIH.

The company is currently developing preventive vaccines against malaria, Zika virus, HIV and the coronavirus as well as hemorrhagic fever viruses like Lassa, Marburg and Ebola; and therapeutic vaccines for chronic Hepatitis B infections and HIV. Additionally, the firm is developing immunotherapies for solid tumor cancers.

This biotechnology firm is at the forefront of forward-thinking vaccine science. Its clinical success has improved its financial position as well its capital structure, which allows it secure long-term funding. Many expect the company to reach numerous vaccine development milestones over the next year, which will benefit both the firm and its shareholders.

GeoVax Labs (GOVX), closed Tuesday's trading session at $1.9, up 71.1712%, on 35,646,599 volume. The average volume for the last 3 months is 14.799M and the stock's 52-week low/high is $1.0901/$10.2405.

Kintara Therapeutics (KTRA)

QualityStocks, TradersPro, MarketClub Analysis, The Online Investor, MarketBeat, The Stock Dork, StockEarnings, Smart money trading, Profitable Trader Authority, PennyStockScholar, pennystockprophet, OTCtipReporter, InvestorPlace, Early Bird and 360 Wall Street reported earlier on Kintara Therapeutics (KTRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kintara Therapeutics, Inc. (NASDAQ: KTRA) (OTC: DMPWW) (FRA: 3DM) is a clinical stage drug development firm that is engaged in the development and commercialization of anti-cancer therapies for the treatment of cancer.

The firm has its headquarters in San Diego, California and was incorporated in 2009, on June 24th by William J. Garner, Dennis M. Brown and Jeffrey A. Bacha. Prior to its name change in August 2020, the firm was known as DelMar Pharmaceuticals Inc. It operates as part of the scientific research and development services industry and serves consumers around the globe. The firm has two companies in its corporate family.

The company is focused on identifying commercial and clinical-stage compounds and establishing a scientific rationale for developing orphan drug indications. It has teamed up with outstanding clinical research and academic institutions across the globe to support the development of its cancer treatments. It is party to a strategic collaboration with Guangxi Wuzhou Pharmaceutical Co. Ltd, which entails manufacturing and selling VAL-083 in China.

The enterprise’s product pipeline comprises of two late-stage therapeutics, including a photodynamic therapy dubbed REM-001 for the treatment of cutaneous metastatic breast cancer; and a DNA-targeting agent dubbed VAL-083 for the treatment of drug-resistant solid tumors like diffuse intrinsic pontine glioma, non-small cell lung cancer, ovarian cancer and glioblastoma multiforme.

The company recently announced its financial results for its fiscal year ended June 2021, with its CEO noting that the company was well-positioned both on its corporate and clinical development front, having entered into purchase agreements with investors to raise monies which will be used for the company’s corporate working capital needs and ongoing clinical studies.

Kintara Therapeutics (KTRA), closed Tuesday's trading session at $0.216, up 20.6704%, on 25,202,443 volume. The average volume for the last 3 months is 49.07M and the stock's 52-week low/high is $0.081/$5.60.

Net Savings Link (NSAV)

QualityStocks, Investor Development Group, MarketClub Analysis, Real Pennies, TheMicrocapNews, Stockgoodies, SmallCapVoice and PennyTrader Publisher reported earlier on Net Savings Link (NSAV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Net Savings Link Inc. (OTC: NSAV) is an integrated technology firm that offers turnkey technological solutions to the legal medical marijuana and hemp industries as well as other areas of the medical industry.

The firm provides its services in the United States and has its headquarters in Cresco, Pennsylvania. Net Savings Link Inc. was established on February 21, 2007.

Net Savings Link Inc. operates through the Global Distribution Corporation, which is a subsidiary it owns. Through it, the firm markets and distributes natural remedies, wellness and supplement products. The firm also offers health and wellness products, including probiotics, mineral and vitamin supplements as well as other nutraceuticals health supplements, under its Nutra Horizon brand name.

Net Savings Link Inc. is also focused on providing various services which include e-commerce and software solutions. Additionally, it provides information technology, patents and trademarks, advisory services and financial services, among others. Net Savings Link Inc. also provides hemp based beer under the brand names Angry Tiger Beer and Tiger Hemp Beer.

Net Savings Link Inc. recently announced that it had acquired a major 25% stake in SBCDF Investment Inc., which is scheduled to launch its STUX product soon. The token; SBC Token Unix X, will be marketed through all major social channels like Medium, Twitter, Telegram, Discord and Reddit. Given that SBC is a force to reckon with not only on Wall Street but also across the globe, NSAV is in for an exciting and fruitful era, which will help the company grow and avail various benefits to its shareholders.

Net Savings Link (NSAV), closed Tuesday's trading session at $0.0072, up 16.129%, on 15,997,538 volume. The average volume for the last 3 months is 418,433 and the stock's 52-week low/high is $0.001/$0.021.

Globavend (GVH)

Premium Stock Picks and Jeff Bishop reported earlier on Globavend (GVH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Globavend Holdings Limited (NASDAQ: GVH) is a holding firm engaged in the provision of integrated cross-border logistics services and air freight forwarding services.

The firm has its headquarters in Perth, Australia and was incorporated in 2016. It operates as part of the integrated freight and logistics industry, under the industrials sector. The firm serves consumers around the globe.

The company’s business spans four cities in Australia, Hong Kong, and New Zealand through its own business presence and the presence of their service providers. Its clients are mainly enterprise customers, e-commerce merchants, or operators of e-commerce platforms.

The enterprise’s service offerings include integrated cross-border logistics services, where it provides customers with a one-stop solution from pre-carriage parcel drop off to parcel consolidation, air-freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It relies on its own proprietary all-in-one shipping solution, which can be connected to the client’s own IT systems, such as customer relationship management (CRM) systems, enterprise resource planning (ERP) systems, booking management systems or point of sale (POS) systems, on one end and the transportation management systems (TMS) of its ground transportation service providers on the other end, to facilitate effective logistics management. In addition to this, it offers fragmented logistics services, which typically include freight forwarding services, to customers and enterprises at their own choice.

The firm recently announced that it had entered a non-binding Memorandum of Understanding to make an equity investment in Top Logistics Australia Pty Limited, a key one stop logistics solutions provider in Australia. This move aligns with the firm’s strategy to solidify its business presence and expansion into Australia and may further boost its business performance.

Globavend (GVH), closed Tuesday's trading session at $0.899799, off by 5.7802%, on 30,331 volume. The average volume for the last 3 months is 10.619M and the stock's 52-week low/high is $0.79/$5.50.

Sharps Technology Inc. (STSS)

RedChip, QualityStocks, StockWireNews, StockStreetWire, Small Cap Firm, MarketClub Analysis, Fierce Analyst, ProTrader, AwesomeStocks, Early Bird and 247 Market News reported earlier on Sharps Technology Inc. (STSS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sharps Technology (NASDAQ: STSS), a medical-device company, has filed forms with the U.S. Securities and Commission to enter into subscription agreements with certain institutional investors. The agreement calls for the company to issue and sell to the investors 2,239,000 shares of common stock, par value $0.0001 per share of the company at a price of $0.38 per share. The agreements are anticipated to results in gross proceeds of $850,820 for STSS. According to the announcement, Aegis Capital Corp. is acting as the exclusive placement agent for the offering, which closed on June 13, 2024. “Additionally, pursuant to a warrant inducement agreement entered into on June 13, 2024, between the company and certain investors, the investors exercised 1,000,000 warrants and the company received $330,000 in gross proceeds, before deducing placement agent fees and commission, and issued an aggregate of 1,000,000 new warrants that are exercisable at $0.45 per share,” stated the company in the SEC filing. “The new warrants will expire on the five-year anniversary of their initial exercise date, which is six months from issuance.”

To view the full press release, visit https://ibn.fm/3QITr

About Sharps Technology Inc.

Sharps Technology, a medical device company, engages in the design, research and development, manufacturing and commercialization of safety syringe products in the United States. The company provides safety syringe products comprising Securgard, Sologard and Sharps Provensa that are ultra-low waste syringes for passive, safety and reuse prevention features. Sharps Technology also develops prefillable syringe systems. The company was incorporated in 2017 and is based in Melville, New York. For more information about the company, visit www.Sharpstechnology.com.

Sharps Technology Inc. (STSS), closed Tuesday's trading session at $0.323, off by 5.0279%, on 1,935,706 volume. The average volume for the last 3 months is 201,277 and the stock's 52-week low/high is $0.173901/$0.94.

Gain Therapeutics (GANX)

MarketBeat and InsiderTrades reported earlier on Gain Therapeutics (GANX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gain Therapeutics (NASDAQ: GANX), a clinical-stage biotechnology company leading the discovery and development of next-generation allosteric therapies, has announced the pricing of an underwritten public offering. The public offering is comprised of 7,116,547 shares of its common stock offered at $1.35 per share and prefunded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. According to the announcement, the prefunded warrants will be immediately exercisable. In addition, the company granted the underwriter a 30-day option to purchase up to 1,222,222 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The public offering is projected to total an estimated $11 million in gross proceeds, excluding the exercise of the underwriter’s option and underwriting discounts and commissions and other offering-related expenses. Gain anticipates using the funds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287, which is designed to treat neurodegenerative diseases including GBA1 Parkinson’s disease, as well as for general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as sole bookrunner for the offering.

To view the full press release, visit https://ibn.fm/Bonxo

About Gain Therapeutics Inc.

Gain Therapeutics is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287 for the treatment of GBA1 Parkinson’s disease is currently being evaluated in a phase 1 clinical trial. Leveraging artificial-intelligence (“AI”)-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models, the company’s Magellan(TM) drug-discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Its AI and machine-learning tools and virtual screening capabilities leverage the emerging on-demand compound libraries covering vast chemical spaces of more than five trillion compounds to identify and select suitable small molecule hits for experimental validation. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology. For more information, visit the company’s website at www.GainTherapeutics.com.

Gain Therapeutics (GANX), closed Tuesday's trading session at $1.28, off by 3.0303%, on 455,473 volume. The average volume for the last 3 months is 7.433M and the stock's 52-week low/high is $1.23/$5.33.

Trump Media & Technology Group Corp. (DJT)

Early Bird, Tim Bohen, The Street, Schaeffer's, QualityStocks, MarketClub Analysis, Eagle Financial Publications, Cabot Wealth, AllPennyStocks and 360 Wall Street reported earlier on Trump Media & Technology Group Corp. (DJT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trump Media & Technology Group (NASDAQ: DJT) has recently faced challenges, notably a significant drop in its stock price. This downturn is linked to the company’s announcement of reaudited finances and the appointment of a new auditor, following issues with the previous one. Trump Media, owned by former President Donald Trump, operates in the competitive social media landscape, contending with giants like Facebook and Twitter for user engagement and advertising revenue.

The stock of Trump Media is currently trading at $30.8, marking a notable decrease of $3.92 or approximately 11.29%. This decline is significant, considering the stock’s performance over the past year, where it reached a high of $79.38 and a low of $12.4. The fluctuation in stock price, with today’s range between $30.76 and $34.98, reflects the market’s reaction to the company’s financial reauditing and auditor change.

With a market capitalization of about $5.44 billion, Trump Media remains a substantial player in the social media industry. However, the trading volume of 3,726,418 shares on the NASDAQ exchange indicates a heightened level of investor interest, possibly due to the recent developments. This level of trading activity suggests that investors are closely monitoring the situation, weighing the implications of the reaudited finances and the auditor switch on the company’s future prospects.

The recent slump in Trump Media’s stock underscores the sensitivity of financial markets to corporate governance and regulatory compliance issues. The appointment of a new auditor, following regulatory scrutiny of the previous one, raises questions about the company’s financial management and reporting practices. These concerns, coupled with the reaudited finances, have evidently impacted investor confidence, as reflected in the stock’s performance.

Overall, the challenges faced by Trump Media highlight the importance of transparency and robust financial oversight in maintaining investor trust. As the company navigates through these issues, its ability to stabilize and potentially recover will be closely watched by investors and industry observers alike.

To view the full press release, visit https://ibn.fm/j86BN

About Trump Media & Technology Group Corp.

The mission of Trump Media & Technology Group Corp. is to end Big Tech’s assault on free speech by opening up the Internet and giving people their voices back. Trump Media & Technology Group operates Truth Social, a social media platform established as a safe harbor for free expression amid increasingly harsh censorship by Big Tech corporations. For more information, visit the company’s website at www.TMTGCorp.com.

Trump Media & Technology Group Corp. (DJT), closed Tuesday's trading session at $31.31, off by 9.8214%, on 10,013,981 volume. The average volume for the last 3 months is 910,732 and the stock's 52-week low/high is $12.40/$79.38.

Cresco Labs Inc. (CRLBF)

QualityStocks, InvestorPlace, Kiplinger Today, Daily Trade Alert, MarketBeat, Cabot Wealth, Top Pros' Top Picks, The Street, The Wealth Report, Wealth Insider Alert, Trading For Keeps, Trades Of The Day, CannabisNewsWire, The Online Investor, Early Bird, Prism MarketView, StreetInsider, wyatt research newsletter, TradersPro and StocksEarning reported earlier on Cresco Labs Inc. (CRLBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recently released federal spending bill includes language that would put an end to the distribution of unregulated hemp products. Provisions in the new spending bill would distinguish between industrial hemp cultivated for food and fiber and plants cultivated to produce cannabinoid extracts.

The definition of hemp, under the new bill, includes naturally occurring and derived cannabinoids. Substances manufactured or synthesized from the plant, such as delta-8 THC, THCP, HHC, THC-O-acetate and delta-10 THC, will no longer meet the legal hemp definition.

The market is filled with these intoxicating products, thriving after the 2018 Farm Bill legalized hemp and left a loophole that allowed delta-8 THC and other psychoactive hemp-derived substances to be sold as alternatives to marijuana.

Congress has some incentive to act on the appropriations before Oct. 1, 2024, when the new fiscal year starts. This is encouraged, particularly since the next farm bill isn’t expected to be finalized until the end of this year or the beginning of 2025.

The intoxicating compounds being targeted are manufactured by synthesizing CBD derived from hemp to produce concentrated psychoactive substances. The effects of these compounds are similar to those produced by delta-9 THC.

Products that contain these substances, commonly referred to as marijuana light and diet weed by consumers, are sold in the form of edibles such as gummies. They are also packaged in bright colors, which appeals to younger individuals. These products are available to both young and old consumers in common retail outlets, including hemp shops, bodegas and convenience stores.

States are also working to remove these products from their jurisdictions, citing safety concerns. This is being supported by medical and recreational cannabis stakeholders, who claim that hemp intoxicants unfairly competed in the market because they don’t incur any fees and are not regulated by states with legal cannabis markets.

The FDA has also given warnings to consumers about hemp-derived intoxicants, stating that these unregulated and unsafe products may contain harmful compounds and should be kept away from children and pets. The agency even sent some companies warning letters for selling products that contained delta-8 THC synthesized from industrial hemp.

A few weeks ago, law enforcement officials from 20 states as well as the District of Columbia penned a letter to Congress urging officials to use the next farm bill to address the spread of these unregulated products. In the letter, the officials noted that these products present a significant threat to public safety and health and benefited untaxed, unaccountable and unregulated market parties.

Cannabis companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) could be watching the goings-on on Capitol Hill to see if the suggested reforms plugging the loopholes in the farm bill are passed into law and how these could impact the cannabis industry.

Cresco Labs Inc. (CRLBF), closed Tuesday's trading session at $1.596, off by 2.0859%, on 331,434 volume. The average volume for the last 3 months is 33.61M and the stock's 52-week low/high is $1.00/$2.77.

Tilray Brands Inc. (TLRY)

Schaeffer's, InvestorPlace, QualityStocks, StockEarnings, StocksEarning, The Street, MarketClub Analysis, MarketBeat, Trades Of The Day, Daily Trade Alert, StockMarketWatch, Kiplinger Today, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, BUYINS.NET, Zacks, Investopedia, CFN Media Group, CNBC Breaking News, The Street Report, StreetAuthority Daily, INO Market Report, Early Bird, Daily Profit, FreeRealTime, CannabisNewsWire, Prism MarketView, Trading For Keeps, Inside Trading, Trading Concepts, InvestmentHouse, Top Pros' Top Picks, The Rich Investor, Tip.us, Eagle Financial Publications, InsiderTrades, Investment House, Investors Alley, Outsider Club, wyatt research newsletter, Wealth Daily, VectorVest, TradersPledge, TheTradingReport, The Night Owl, StrategicTechInvestor, Money Morning, Rick Saddler, InvestorsObserver Team, AllPennyStocks, MarketClub, Marketbeat.com, Louis Navellier, Jim Cramer, Jason Bond, InvestorsUnderground and Stock Up Featured reported earlier on Tilray Brands Inc. (TLRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In 2014, a Denver-based cannabis dispensary, 3D Cannabis, made history as the first seller of legal marijuana. Over a decade later, the dispensary bears a sign saying it is “temporarily closed,” with the building’s doors and windows boarded up and the parking lot strewn with trash, symbolizing the challenges facing Colorado’s marijuana market.

Once a thriving success, the industry is now marked by failed entities and struggling entrepreneurs due to regulatory challenges, market saturation and increased competition from neighboring states.

The market’s sales peaked in 2020 at $2.2 billion. But by 2023, revenues had fallen to $1.5 billion, which led to restructuring, closures and layoffs. The decrease has also affected state finances; in the most recent fiscal year, Colorado’s marijuana tax receipts dropped significantly to $282 million from prior years.

Several factors have contributed to the industry’s struggles. An oversupply of cannabis following the pandemic caused prices to drop sharply. The rise of cheap, unregulated hemp-derived products added further pressure. Additionally, the federal illegality of marijuana means operators face high taxes and costly rules.

However, the primary challenge has been the rapid spread of legalization across the country, with neighboring states such as Arizona and New Mexico now having their own legal cannabis markets and disrupting Colorado dispensaries, particularly those near the southern border. Tourists who previously flocked to Colorado for legal marijuana now have closer options, and even Texans are finding satisfying alternatives in hemp products available locally.

While some business owners have managed to survive by adapting, many have closed or moved to other states. The number of marijuana licenses in Colorado decreased by more than 16%, similar to the number of marijuana jobs, marking the second consecutive year of employment losses.

Maggie’s Farm, a retailer in southern Colorado, is one prominent example: out of its eight dispensaries, five are closed. Similarly, one of the biggest marijuana companies in the United States, Curaleaf, stated in January of last year that it was closing its cultivation and production facilities in Colorado.

In 2020, the pandemic helped the state’s cannabis industry at first since more people were staying at home and making more purchases, thanks to stimulus checks. However, as the pandemic’s dynamics shifted, the rush to expand cannabis production resulted in a glut of supply, causing prices to drop from nearly $1,700 a pound to about $700 a pound.

Companies such as Veritas Fine Marijuana, a wholesale grower, initially expanded their production but later had to downsize and change their cultivation methods to stay competitive. At its peak, Veritas employed 144 people; currently, it has only 21 employees.

Native Roots, another significant player, experienced similar challenges. Its Mothership growth facility in Denver used to produce around 32,000 pounds of cannabis annually but had to cut production by half by mid-2023. The company is cautiously increasing production again while closely monitoring market conditions. Native Roots benefits from having 21 dispensaries across the state, helping it weather the downturn better than some competitors.

Moreover, states compete on regulations, further complicating the market. New Mexico, for instance, allows adults to purchase up to two ounces of marijuana, double Colorado’s limit. Additionally, edibles in New Mexico can contain higher dosages. These higher limits attract residents from states without legal weed, who previously traveled to Colorado.

Despite the industry’s struggles, Colorado’s early legalization has produced successful entrepreneurs who have expanded beyond Colorado’s borders. Nancy Whiteman, for instance, founded Wana in 2010, focusing on marijuana-infused edibles. Wana has grown significantly, with operations in 17 states and Puerto Rico, and plans to enter the European market. Whiteman’s success culminated in a lucrative deal with Canopy Growth, a major Canadian cannabis producer valued at $350 million.

Major marijuana entities such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) could be assessing the changing market dynamics and planning their future strategic direction in order to remain at the top.

Tilray Brands Inc. (TLRY), closed Tuesday's trading session at $1.69, even for the day, on 7,615,054 volume. The average volume for the last 3 months is 1.369M and the stock's 52-week low/high is $1.50/$3.40.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, Dynamic Wealth Report, PsychedelicNewsWire, StreetInsider, MarketClub Analysis, Small Caps, Uncommon Wisdom, Marketbeat.com, CRWEWallStreet, CRWEPicks, InsiderTrades, CRWEFinance, BestOtc, DrStockPick, PennyOmega, PennyToBuck, Schaeffer's, StockHotTips, TraderPower, Awareness Stocks, StockOodles, Street Insider, The Street, TopPennyStockMovers, Broad Street and ProTrader reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Therapeutic interest in psychedelics has grown as researchers learn more about the potential of these substances to manage the symptoms of different mental-health conditions and improve the well-being of individuals. Now, new research has determined that psychedelic experiences can cause a decrease in death anxiety, possibly by changing a person’s metaphysical beliefs. This discovery creates new approaches for understanding how these substances may help people deal with existential fears.

For their study, researchers focused on determining if changes in core beliefs on consciousness and the nature of reality could be a key factor in decreasing death anxiety after psychedelics were administered. The researchers recruited 155 participants who had experienced psychedelic trips that they felt had amended their anxieties or attitudes about death. All participants were required to be fluent in English, be at least 18 years of age, and have experience with at least one classic psychedelic, such as DMT, LSD, ayahuasca, mescaline or psilocybin.

The participants were all recruited via social media and online platforms, centering on groups specific to psychedelics.

Each participant was required to complete an anonymous online poll, where they gave details about their use of psychedelics as well as their most significant experience with the drugs. In addition to this, they were asked questions on their attitudes and beliefs about death three months prior to and three months after their psychedelic experiences.

The researchers determined that a total of 81 participants reported a reduction in their anxiety regarding death, as indicated by a negative change score, while 57 participants reported an increase, as indicated by a positive change score. Additionally, 17 participants reported no change.

Participants also demonstrated a considerable overall increase in beliefs that focused on the separation of body and mind, particularly beliefs on nonnaturalism and the existence of another realm apart from the physical.

One important finding was the correlation between changes in the belief that consciousness is a basic quality of all things in the universe and changes in death anxiety. This suggests that believing that consciousness extends beyond physical death may help reduce fears of death.

The research did have some limitations, however, including its cross-sectional model, which limited the ability to establish causal relationships between changes in metaphysical beliefs, psychedelic experiences and a drop in death anxiety.

The retrospective nature of the study was also a limitation because it meant that the recall accuracy of the participants could be biased by their present attitudes and beliefs.

The research was authored by Sam G. Moreton, Kayla J. Giese and Noah N. Barr. Its findings were reported in “Death Studies.”

Many enterprises like atai Life Sciences N.V. (NASDAQ: ATAI) are conducting psychedelic drug development programs. As these efforts advance, more information could become available about the effects that different psychedelics can have on people’s health and wellness.

atai Life Sciences N.V. (ATAI), closed Tuesday's trading session at $1.27, off by 5.2239%, on 1,099,307 volume. The average volume for the last 3 months is 16.549M and the stock's 52-week low/high is $1.025/$2.85.

Alibaba Group Holding Ltd. (BABA)

InvestorPlace, The Street, Kiplinger Today, Schaeffer's, MarketClub Analysis, Money Morning, Zacks, StreetInsider, Trades Of The Day, Daily Trade Alert, Marketbeat, Market Intelligence Center Alert, StocksEarning, Investopedia, The Online Investor, Wealth Insider Alert, StreetAuthority Daily, Early Bird, ProfitableTrading, CustomerService, Marketbeat.com, TopStockAnalysts, Louis Navellier, Uncommon Wisdom, GorillaTrades, TipRanks, CNBC Breaking News, Cabot Wealth, StockEarnings, Top Pros' Top Picks, AllPennyStocks, Profit Confidential, The Wealth Report, Options Elite, QualityStocks, Investors Alley, Total Wealth, Street Insider, Money and Markets, INO.com Market Report, Daily Profit, Barchart, The Street Report, Wyatt Investment Research, SmallCapVoice, Investing Daily, StrategicTechInvestor, Market Intelligence Center, Insider Wealth Alert, Average Joe Options, Power Profit Trades, Daily Wealth, Trade of the Week, Investing Signal, INO Market Report, MarketTamer, Wealth Daily, WStreet Market Commentary, BUYINS.NET, Wall Street Daily, Short Term Wealth, MarketWatch, Trading Concepts, The Best Newsletters, FreeRealTime, Trader Prep, Inside Investing Daily, InvestmentHouse, Visual Capitalist, Dynamic Wealth Report, 24/7 Trader, TheOptionSpecialist, ChineseWire, Rick Saddler, The Weekly Options Trader, Energy and Capital, Agora Financial, Investing Lab, Investment U, Daily Dividends, MarketArmor.com, Investors Underground, InvestorsHQ, Wealthpire Inc., OptionAlarm News, SureMoney, Investing Futures, Navellier Growth, Eagle Financial Publications, DividendStocks, Dividend Opportunities, Direction Alerts, Weekly Wizards, wyatt research newsletter, MarketDeal, TheoTrade, wealthmintrplus, BillionDollarClub, Beat The Street, Stock Gumshoe, SmallCapNetwork, Atomic Pennies, Profits Run, Shah's Insights & Indictments, 24-7 Stock Alert, StockMarketWatch, Jim Cramer, InvestorGuide, Investor Guide, The Growth Stock Wire, Investment House, Investiv, Rockwell Trading, InvestorsObserver Team, Market Authority, The Night Owl, Summa Money, Inside Trading, Energy & Resources Digest, Wallstreet Journal, Kiplinger’s Weekly Update, Hit and Run Candle Sticks, Greenbackers, The Trading Report, Goldman Small Cap Research, Liberty Through Wealth, Financial Freedom Post, Equities.com, Terry's Tips and The Stock Dork reported earlier on Alibaba Group Holding Ltd. (BABA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Qwen2 Series, Alibaba Cloud’s most recent language model series, has outperformed every other open-source language learning model (LLM) in various benchmarks to emerge at the top of the LLM Leaderboard. Trained with nearly 30 languages, Alibaba’s LLM surpassed the competition soon after its launch, thanks to its enhanced safety alignment as well as the improved performance it offers.

This latest LLM series from Alibaba Group Holding Ltd. (NYSE: BABA) comprises several instruction-turned language models ranging from 0.5 to 72 billion parameters in size, base languages and a Mixture-of-Experts (MoE). Thanks to these updated capabilities, Qwen2 raced to the number-one spot on Hugging Face’s Open LLM Leaderboard. Hugging Face is a collaborative artificial intelligence platform where Qwen2 is currently available for both research and commercial purposes.

According to Zhou Jingren, chief technology officer at Alibaba Cloud, the company hopes to develop the “most open cloud in the AI era,” make the burgeoning artificial intelligence segment more accessible and increase computing power inclusivity. With technology companies such as OpenAI developing more advanced AI by the day, Alibaba Cloud and other cloud providers are already working to integrate the technology into their systems.

Alibaba Cloud plans to pull ahead of the pack with offerings such as the Qwen2, which is available on the collaborative AI platform Hugging Face as well as ModelScope, Alibaba’s AI model community. Alibaba leveraged optimized training methods in the development of the Qwen2-72B model, allowing it to beat other top open-source language learning models in 15 benchmarks, including reasoning, mathematics, multilingual capability, language generation and coding.

The model has also displayed the capacity to handle up to 128K tokens, the highest number of tokens a language model can remember while it generates text. Alibaba Cloud used 27 languages including English, Chinese, Spanish, Italian, Hebrew, Persian, German and Arabic to boost Qwen2’s multilingual abilities. The Chinese technology company also used a technique called Group Query Attention to increase the Qwen2 Model’s speed and lower memory use by optimizing the balance between model performance and computational efficiency.

Aside from Qwen2’s extremely high-level linguistics and mathematics capabilities, its output also indicates that the model aligns better with human values, giving it one more edge over other open-source language learning models. The MT-bench revealed that Qwen2 scored highly in instruction following and multiturn conversational ability, two elements that are crucial to a chatbot’s interactions with people.

Alibaba included human feedback to help the Qwen2 model align with human values better and perform better in terms of responsibility and safety. This allows Alibaba’s LLM to deal with unsafe multilingual queries associated with criminal activities, such as privacy violations and fraud, and prevents it from being misused by bad players.

Alibaba Group Holding Ltd. (BABA), closed Tuesday's trading session at $74.46, off by 0.1207243%, on 10,305,285 volume. The average volume for the last 3 months is 255,320 and the stock's 52-week low/high is $66.63/$102.50.